Sugi Predict

Sugi Predict / Compounds / SCHEMBL10072451

SCHEMBL10072451

SCHEMBL10072451

CCC(C)n1nc(Cl)ccc1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ MAP4K1 Q92918 2/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ MAPT P10636 3/20 0.33
▸ KDM4E B2RXH2 3/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ HCAR3 P49019 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ GLA P06280 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ CDK4 P11802 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL23649996 0.91 L3MBTL1 (0.39) L3MBTL1MAP4K1HTR2AHTR2CHTR2B
SCHEMBL10072113 0.81 BMPR1B (0.34) HTR2AHTR2CHTR2BMEN1CYP1A2
SCHEMBL12129485 0.80 MAP4K1 (0.37) L3MBTL1MAP4K1HTR2AHTR2CHTR2B
SCHEMBL29865221 0.79 MAP4K1 (0.38) L3MBTL1MAP4K1HTR2AHTR2CHTR2B
SCHEMBL23649578 0.79 MAP4K1 (0.38) L3MBTL1MAP4K1HTR2AHTR2CHTR2B
SCHEMBL23649781 0.79 MAP4K1 (0.38) L3MBTL1MAP4K1HTR2AHTR2CHTR2B
SCHEMBL23649576 0.79 MAP4K1 (0.38) L3MBTL1MAP4K1HTR2AHTR2CHTR2B
SCHEMBL23649810 0.79 MAP4K1 (0.38) L3MBTL1MAP4K1HTR2AHTR2CHTR2B
SCHEMBL23649780 0.79 MAP4K1 (0.38) L3MBTL1MAP4K1HTR2AHTR2CHTR2B
Hydrochloric Acid SCHEMBL23649831 0.77 MAP4K1 (0.38) L3MBTL1MAP4K1HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115279771-B MAP4K1 inhibitors 缆图药品公司 2025-03-21 — — CN disclosed
US-12042495-B2 MAP4K1 inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2024-07-23 — — US disclosed
US-20230140954-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-05-11 — — US disclosed
US-20230140954-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-05-11 — — US disclosed
US-20230140954-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-05-11 — — US disclosed
US-11534441-B2 MAP4K1 inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2022-12-27 — — US disclosed
US-11534441-B2 MAP4K1 inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2022-12-27 — — US disclosed
EP-4090663-A1 MAP4K1 INHIBITORS Blueprint Medicines Corporation (US) 2022-11-23 — — EP disclosed
CN-115279771-A MAP4K1 inhibitors 缆图药品公司 2022-11-01 — — CN disclosed
US-20220323438-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2022-10-13 — — US disclosed
WO-2021146370-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2021-07-22 — — WO disclosed
WO-2021146370-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2021-07-22 — — WO disclosed
US-8318742-B2 Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2012-11-27 — — US disclosed
US-20120028987-A1 Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2012-02-02 — — US disclosed
US-8063070-B2 Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2011-11-22 — — US disclosed
US-7790750-B2 Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 — — US disclosed
US-20100210657-A1 Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2010-08-19 — — US disclosed
US-RE40793-E1 Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2009-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11534441-B2 MAP4K1 inhibitors MAP4K1, MAP4K4, MAP4K2 L3MBTL1 2368/4885MAP4K1 1/4885HTR2A 4054/4885
US-20220323438-A1 MAP4K1 INHIBITORS MAP4K1, MAP4K4, MAP4K2 L3MBTL1 2368/4885MAP4K1 1/4885HTR2A 4054/4885
US-20120028987-A1 Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives HRH2, SLC10A2, HRH4 L3MBTL1 4449/4885MAP4K1 1483/4885HTR2A 1338/4885
US-20230140954-A1 MAP4K1 INHIBITORS MAP4K1, MAP4K4, MAP4K2 L3MBTL1 2368/4885MAP4K1 1/4885HTR2A 4054/4885
US-20100210657-A1 Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives HRH2, HRH4, PGC L3MBTL1 4445/4885MAP4K1 1387/4885HTR2A 1066/4885
US-12042495-B2 MAP4K1 inhibitors MAP4K1, MAP4K4, MAP4K2 L3MBTL1 2368/4885MAP4K1 1/4885HTR2A 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.